Skip to main content
AVECHO BIOTECHNOLOGY LIMITED logo

AVECHO BIOTECHNOLOGY LIMITED — Investor Relations & Filings

Ticker · AVE ISIN · AU0000047441 LEI · 529900FA9G9T82C2LV25 ASX Manufacturing
Open in API
Filings indexed 880 across all filing types
Latest filing 2026-04-28 Share Issue/Capital Cha…
Country AU Australia
Listing ASX AVE

About AVECHO BIOTECHNOLOGY LIMITED

https://avecho.com.au/

Avecho Biotechnology Limited develops and commercializes human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®). Derived from Vitamin E, TPM® is designed to enhance the solubility and absorption of active ingredients through the skin and digestive tract. The company focuses on applying this technology to pharmaceuticals, nutraceuticals, and animal health sectors. A primary area of development includes medicinal cannabis, where Avecho has produced high-bioavailability cannabidiol (CBD) softgel capsules for therapeutic use. The company’s portfolio also includes applications in pain management and dermatology, leveraging TPM® to improve the delivery of poorly soluble molecules and enhance the efficacy of existing treatments.

Recent filings

Filing Released Lang Actions
Letter to Optionholders - Notice of Expiry of Listed Options 7 pages 796.8KB
Share Issue/Capital Change Classification · 95% confidence The document is an ASX announcement dated 29 April 2026 from Avecho Biotechnology Limited regarding the notification of expiry of listed options exercisable at a specified price by a certain expiry date. It includes detailed instructions to option holders on exercising their options, payment details, and the cessation of trading of these options prior to expiry. The content is focused on informing shareholders about the expiry and exercise process of listed options, which is a capital market event related to share options. There is no financial statement, earnings data, or management discussion present. The document is not a report but an announcement related to capital structure changes (expiry and exercise of options). Therefore, the appropriate classification is a Share Issue/Capital Change announcement (SHA). The document length and detail confirm it is not a brief notice but a full announcement. Confidence is high due to clear content and context.
2026-04-28 English
Notice of Annual General Meeting/Proxy Form 21 pages 481.4KB
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a Notice of Annual General Meeting including the Explanatory Statement and Proxy Form, sent to shareholders to solicit their votes on resolutions. This aligns with the Proxy Solicitation & Information Statement category (Code: PSI), rather than an AGM presentation, results announcement, or full annual report.
2026-04-23 English
Avecho to present at NWR Virtual Healthcare Conference 3 pages 195.8KB
Investor Presentation Classification · 95% confidence The document is an ASX announcement dated 24 March 2026 about Avecho Biotechnology Limited presenting at the NWR Virtual Healthcare Conference. It includes details about the presentation time, registration link, company background, and information about their Phase III clinical trial program. There are no financial statements, earnings data, or detailed financial analysis present. The document is primarily an announcement of an upcoming investor presentation event rather than the presentation itself or a financial report. It does not contain any voting results, management changes, or regulatory filings. Given the content and purpose, this fits best as an Investor Presentation announcement (IP). The document length is 8821 characters, which is consistent with a detailed announcement but not a full report. Therefore, the classification is Investor Presentation (IP) with high confidence.
2026-03-23 English
Avecho completes recruitment for Phase III interim analysis 3 pages 219.4KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 2 March 2026 from Avecho Biotechnology Limited. It reports the completion of recruitment for the interim analysis cohort of a pivotal Phase III clinical trial and discusses upcoming interim analysis results expected in June 2026. The content focuses on clinical trial progress, commercial partnerships, market potential, and forward-looking statements. There are no financial statements, detailed financial performance data, or regulatory filings such as annual or quarterly reports. The document is a corporate announcement updating the market on a significant milestone in the clinical trial process, which is a capital/financing or operational update related to the company's development pipeline and commercial strategy. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. The best fitting category is Capital/Financing Update (CAP) as it relates to progress in a value-defining milestone and commercial partnerships that impact the company's capital and valuation.
2026-03-01 English
Annual Report 31 December 2025 60 pages 3.0MB
Annual Report Classification · 100% confidence The document is titled 'Avecho Biotechnology Limited Appendix 4E Preliminary final report' and covers the year ended 31 December 2025. It includes detailed financial results, directors' report, auditor's independence declaration, consolidated financial statements, notes, and an independent auditor's report. The document references the full Annual Report being attached and audited. The content includes comprehensive financial data, operational review, corporate activities, and detailed financial statements, which are characteristic of an Annual Report. The length of the document (15,000 characters) and the presence of full financial statements confirm it is not merely an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2025
2026-02-26 English
Appendix 4G and Corporate Governance Statement 25 pages 878.0KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It is a form used by Australian listed entities to confirm compliance with corporate governance disclosure requirements. The document includes a checklist of governance principles and recommendations, indicating which have been followed or not, and points to where the detailed corporate governance statement can be found (either in the annual report or on the company's website). The document explicitly states it is not a substitute for the corporate governance statement but serves as a verification tool lodged alongside the annual report. It does not contain the full corporate governance statement or detailed financial data but is a regulatory compliance filing related to governance disclosures. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-02-26 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.